Literature DB >> 11025598

Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.

E Granados1, R de La Cámara, L Madero, M A Díaz, P Martín-Regueira, J L Steegmann, R Arranz, A Figuera, J M Fernández-Rañada.   

Abstract

BACKGROUND AND OBJECTIVES: There is only limited experience with conditioning regimens based on busulfan for patients with acute lymphoblastic leukemia (ALL). Therefore, the aim of this study was to compare the event-free survival (EFS), transplant-related mortality (TRM) and the probability of relapse (PR) of patients undergoing hematopoietic cell transplantation (HCT) for ALL conditioned with or without total body irradiation (TBI). DESIGN AND METHODS: The study sample consisted of 156 patients conditioned with regimens based on TBI (n=114) or on high doses of oral busulfan (BU) (n=42). Most of the BU group received phenytoin as prophylaxis for seizures. The median follow-up was 6 years.
RESULTS: EFS at 6 years was 43% (95% CI 35%-51%) versus 22% (95% CI 10%-34%) in the TBI and BU subsets respectively (p=0.01). TRM at 18 months was 22% and 17% in the BU and TBI groups (p=0.24), respectively. At 3 years actuarial PR was 71% in the BU group and 47% in the TBI group (p=0.01). In the multivariable analysis, a worse EFS was associated with BU, relative risk (RR) 1.7; advanced disease versus 1st and 2nd complete remission (CR) at HCT, RR 2.5; absence of chronic graft-versus-host disease, RR 1.8; development of veno-occlusive disease RR 2.2 and shorter CR duration before transplant. INTERPRETATION AND CONCLUSIONS. TBI was associated with a lower relapse rate and better EFS, even in patients in 1(st )and 2(nd) CR, than schemes based on high doses of busulfan. This suggests that conditioning regimens based on TBI should remain the standard method of preparative regimen for patients with ALL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025598

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.

Authors:  Zinaida Peric; Myriam Labopin; Christophe Peczynski; Emmanuelle Polge; Jan Cornelissen; Ben Carpenter; Mike Potter; Ram Malladi; Jenny Byrne; Harry Schouten; Nathalie Fegueux; Gerard Socié; Montserrat Rovira; Jurgen Kuball; Maria Gilleece; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-05-02       Impact factor: 5.483

2.  Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation.

Authors:  Mitchell Sabloff; Saurabh Chhabra; Tao Wang; Caitrin Fretham; Natasha Kekre; Allistair Abraham; Kehinde Adekola; Jeffery J Auletta; Christopher Barker; Amer M Beitinjaneh; Christopher Bredeson; Jean-Yves Cahn; Miguel Angel Diaz; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Usama Gergis; Eva Guinan; Betty K Hamilton; Shahrukh Hashmi; Peiman Hematti; Gerhard Hildebrandt; Leona Holmberg; Sanghee Hong; Hillard M Lazarus; Rodrigo Martino; Lori Muffly; Taiga Nishihori; Miguel-Angel Perales; Jean Yared; Shin Mineishi; Edward A Stadtmauer; Marcelo C Pasquini; Alison W Loren
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-29       Impact factor: 5.742

3.  Identification of a murine CD45-F4/80lo HSC-derived marrow endosteal cell associated with donor stem cell engraftment.

Authors:  Kathleen M Overholt; Satoru Otsuru; Timothy S Olson; Adam J Guess; Victoria M Velazquez; Laura Desbourdes; Massimo Dominici; Edwin M Horwitz
Journal:  Blood Adv       Date:  2017-12-14

4.  Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation.

Authors:  Claudia Linsenmeier; Daniel Thoennessen; Laura Negretti; Jean-Pierre Bourquin; Tino Streller; Urs Martin Lütolf; Susanne Oertel
Journal:  Strahlenther Onkol       Date:  2010-11-08       Impact factor: 3.621

5.  Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.

Authors:  Omer Jamy; Sankalp Arora; Ruby Meredith; Donna Salzman; Antonio Di Stasi; Kentaro Minagawa; Shin Mineishi; Ayman Saad
Journal:  Bone Marrow Transplant       Date:  2022-07-09       Impact factor: 5.174

6.  Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.

Authors:  Sakurako Izaki; Hiroaki Goto; Kumiko Okuda; Motoi Matsuda; Yuka Watanabe; Kenichirou Fujioka; Noriyuki Hanzawa; Hiroko Sumita; Hiroyuki Takahashi; Shoko Goto; Sumio Kai; Haruyuki Sekiguchi; Tetsunori Funabiki; Hideki Sasaki; Koichiro Ikuta; Shumpei Yokota
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

7.  Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.

Authors:  X Cahu; M Labopin; S Giebel; M Aljurf; S Kyrcz-Krzemien; G Socié; M Eder; F Bonifazi; D Bunjes; S Vigouroux; M Michallet; M Stelljes; T Zuckerman; J Finke; J Passweg; I Yakoub-Agha; D Niederwieser; G Sucak; H Sengeløv; E Polge; A Nagler; J Esteve; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-11-30       Impact factor: 5.483

8.  Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.

Authors:  Ho Cheol Shin; Yoo Jin Lee; Joon Ho Moon; Soo Jung Lee; Byung Woog Kang; Yee Soo Chae; Jong Gwang Kim; Jun Young Choi; Jong Won Seo; Yu Kyung Kim; Jang Soo Suh; Sang Kyun Sohn
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

9.  Once-a-day fractionated total-body irradiation: A regimen tailored to local logistics in allogeneic stem cell transplantation for acute lymphoblastic leukemia.

Authors:  Nour Ben Abdeljelil; Saloua Ladeb; Talel Dahmani; Lotfi Kochbati; Amel Lakhal; Rym El Fatmi; Lamia Torjemane; Dorra Belloumi; Mounir Besbes; Farouk El Benna; Chiraz Nasr Ben Ammar; Tarek Ben Othman
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-28

10.  Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.

Authors:  C Greil; M Engelhardt; G Ihorst; J Duque-Afonso; K Shoumariyeh; H Bertz; R Marks; R Zeiser; J Duyster; J Finke; R Wäsch
Journal:  Bone Marrow Transplant       Date:  2020-10-31       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.